Weekly Research Analysts’ Ratings Changes for Humana (HUM)

A number of research firms have changed their ratings and price targets for Humana (NYSE: HUM):

• 8/2/2022 – Humana had its price target raised by analysts at Morgan Stanley from $453.00 to $494.00. They now have an “equal weight” rating on the stock.
• 7/29/2022 – Humana was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 7/28/2022 – Humana had its price target raised by analysts at SVB Leerink LLC from $535.00 to $540.00. They now have an “outperform” rating on the stock.
• 7/28/2022 – Humana had its price target raised by analysts at Oppenheimer Holdings Inc. from $510.00 to $520.00. They now have an “outperform” rating on the stock.
• 7/28/2022 – Humana had its price target raised by analysts at Barclays PLC from $500.00 to $570.00. They now have a “maintains” rating on the stock.
• 7/28/2022 – Humana had its price target raised by analysts at Mizuho from $500.00 to $529.00. They now have a “maintains” rating on the stock.
• 7/28/2022 – Humana had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $450.00 to $514.00.
• 7/19/2022 – Humana was given a new $548.00 price target on by analysts at Credit Suisse Group AG.
• 7/14/2022 – Humana had its price target raised by analysts at Truist Financial Co. from $490.00 to $550.00. They now have a “hold” rating on the stock.
• 6/16/2022 – Humana is now covered by analysts at Loop Capital. They set a “buy” rating and a $510.00 price target on the stock.

Humana Trading Up 0.7 %

NYSE HUM opened at $481.80 on Thursday. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.73. Humana Inc. has a twelve month low of $351.20 and a twelve month high of $497.47. The firm has a market capitalization of $60.97 billion, a PE ratio of 19.67, a P/E/G ratio of 1.42 and a beta of 0.77. The stock’s 50 day moving average is $464.30 and its 200 day moving average is $441.89.

Humana (NYSE:HUM – Get Rating) last announced its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.67 by $1.00. The business had revenue of $23.66 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Humana had a return on equity of 18.42% and a net margin of 3.52%. The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.89 earnings per share. Research analysts forecast that Humana Inc. will post 24.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Humana by 15.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 61,164 shares of the insurance provider’s stock worth $28,469,000 after purchasing an additional 8,066 shares during the last quarter. Riverview Trust Co purchased a new stake in Humana during the first quarter valued at $32,000. Transcend Capital Advisors LLC increased its position in Humana by 18.3% during the first quarter. Transcend Capital Advisors LLC now owns 587 shares of the insurance provider’s stock valued at $255,000 after acquiring an additional 91 shares during the last quarter. CWM LLC purchased a new stake in Humana during the fourth quarter valued at $218,000. Finally, CCLA Investment Management Ltd increased its position in Humana by 1.4% during the first quarter. CCLA Investment Management Ltd now owns 218,232 shares of the insurance provider’s stock valued at $95,075,000 after acquiring an additional 3,034 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.